SHOP APOTHEKE EUROPE: Pace of growth once again increased in 2017.

NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.

SHOP APOTHEKE EUROPE: Pace of growth once again increased in 2017.

• Consolidated revenues up by +60% to EUR 284 m.
• International business volume significantly expanded at EUR 74 m (+143%).
• Investment in process automation further progressed.

Venlo/Cologne, 24 January 2018. SHOP APOTHEKE EUROPE N. V., the leading online pharmacy in continental Europe, achieved preliminary consolidated revenues of EUR 284 m in the financial year 2017 (balance sheet date: 31 December). Compared to the previous year, this represents an increase of +60%.

The dynamic sales development was driven by the successful increase in the number of active customers in Europe from 1.8 m as of the end of 2016 to about 2.7 m by the end of 2017 as well as the corresponding increase in order volume. In addition to organic growth, Europa Apotheek, acquired in the fourth quarter and consolidated since 8 November 2017, contributed EUR 25 m to the sales growth.

In its core segment "Germany", SHOP APOTHEKE EUROPE increased revenues by 44% to
EUR 209 m (previous year: EUR 146 m). The strongest growth drivers were once again the international markets, including Austria, France, Belgium, the Netherlands, Spain and Italy. Here, SHOP APOTHEKE EUROPE increased its business by more than 143%. Accordingly, revenues in the segment "International" climbed to EUR 74 m (previous year: EUR 30 m). The "Germany Services" segment, which comprises webshop services, generated net revenues of EUR 0.8 m (previous year: EUR 2.5 m) after elimination of intra-group services. In future, this segment will be integrated into the segment "Germany".

Dr. Ulrich Wandel, CFO of SHOP APOTHEKE EUROPE, comments on the financial year 2017:

"Overall, we are very satisfied with our successful growth in the financial year 2017. We have increased the share of our international revenues significantly from 17% in 2016 to c. 26% in 2017 and have consistently continued to invest in the expansion and automation of our warehouse, logistics and IT infrastructure. With the acquisition of Europa Apotheek, we have broadened our product range with prescription drugs for additional German and future international growth. With an overall +60% increase in revenues, we have achieved our ambitious target for 2017 and once again substantially expanded our market leadership in all relevant European markets. In this way, we have created the base for continued strong growth in our European target markets in the financial year 2018."

SHOP APOTHEKE EUROPE will publish the detailed results for the financial year 2017 with presentation of the consolidated financial statements on 12 March 2018.

FINANCIAL CALENDAR 2018

12 March 2018	Publication of results for the financial year 2017
26 April 2018	Annual General Meeting
15 May 2018	Publication of the results for Q1 2018
14 August 2018	Publication of the results for H1 2018
14 November 2018	Publication of the results for Q3 2018

 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly enhanced its European market leadership with an extended product range for the whole family in the areas of OTC, beauty and care products as well as prescription drugs.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and The Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to about 2.7 m active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.


MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobil: +49 152 28 50 63 61
E-Mail: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobil: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Telefone: +31 77 850 6117
E-Mail: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This publication is an advertisement.
This communication constitutes neither an offer to sell nor a solicitation to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is not a securities prospectus. No public offering of any securities of Shop Apotheke Europe N.V. is being made.

Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.